EXHIBIT 4.35 ASSET PURCHASE AGREEMENTAsset Purchase Agreement • June 28th, 2007 • Healthcare Technologies LTD • In vitro & in vivo diagnostic substances
EXHIBIT 4.35 Date: October 18, 2007 The undersigned, each of which is a party to that certain Asset Purchase Agreement (the "AGREEMENT"), dated January 16, 2007, by and among Healthcare Technologies Ltd., an Israeli company, Nexgen Biofuels, Inc., a...Asset Purchase Agreement • January 7th, 2008 • Healthcare Technologies LTD • In vitro & in vivo diagnostic substances
The undersigned, each of which is a party to that certain Asset Purchase Agreement (the "AGREEMENT"), dated January 16, 2007, by and among Healthcare Technologies Ltd., an Israeli company, Nexgen Biofuels, Inc., a Delaware corporation, MAC Bioventures, Inc., a Belize corporation and Gamida For Life, B.V., a Netherlands corporation, as amended, hereby agree that the date "October 31, 2007" which appears in Sections 1.65 and 12.1.2 of the Agreement shall be deemed to read "December 31, 2007".
EXHIBIT 4.34 SHARE TRANSFER AGREEMENT This SHARE TRANSFER AGREEMENT (this "AGREEMENT") made as of the ________th day of April, 2005, by and among Healthcare Technologies Ltd. (the "SELLER") and Gamida for Life, BV, a company incorporated under the...Share Transfer Agreement • June 29th, 2005 • Healthcare Technologies LTD • In vitro & in vivo diagnostic substances
EXHIBIT 4.30 NON-EXCLUSIVE LICENSE AGREEMENT BETWEEN THE WASHINGTON RESEARCH FOUNDATION AND SAVYON DIAGNOSTICS. LTD. This License Agreement (hereinafter, the "Agreement") is made and is effective the day of the last of the Parties to sign...Non-Exclusive License Agreement • August 5th, 2003 • Healthcare Technologies LTD • In vitro & in vivo diagnostic substances • Washington
NOTE AND WARRANT PURCHASE AGREEMENTNote and Warrant Purchase Agreement • March 10th, 2010 • Nexgen Biofuels LTD • Industrial organic chemicals • New York
This NOTE AND WARRANT PURCHASE AGREEMENT (this “Agreement”) is entered into as of March 2, 2010, by and between Laxai Pharma, Ltd, an Israeli company formerly known as NexGen Biofuels Ltd., and trading on the OTC Bulletin Board under the symbol “NXGNF” (the “Company”), and UTA Capital LLC, a Delaware limited liability company (the “Purchaser”).
EXHIBIT 4.31 COLLABORATION AGREEMENT BETWEEN PROCHON BIOTECH AND SAVYON DIAGNOSTICS FOR THE DEVELOPMENT OF PRONTO(TM) FGFR3 KIT 1. ProChon Biotech Ltd. ("ProChon") is engaged in the development and possesses the rights to certain therapeutic agents...Collaboration Agreement • August 5th, 2003 • Healthcare Technologies LTD • In vitro & in vivo diagnostic substances
ASSET PURCHASE AGREEMENTAsset Purchase Agreement • March 9th, 2010 • Nexgen Biofuels LTD • Industrial organic chemicals • Florida
NOTE AND WARRANT PURCHASE AGREEMENTNote and Warrant Purchase Agreement • March 9th, 2010 • Nexgen Biofuels LTD • Industrial organic chemicals • New York
This NOTE AND WARRANT PURCHASE AGREEMENT (this “Agreement”) is entered into as of March 2, 2010, by and between Laxai Pharma, Ltd, an Israeli company formerly known as NexGen Biofuels Ltd., and trading on the OTC Bulletin Board under the symbol “NXGNF” (the “Company”), and UTA Capital LLC, a Delaware limited liability company (the “Purchaser”).
DISTRIBUTION AGREEMENTDistribution Agreement • March 17th, 2003 • Healthcare Technologies LTD • In vitro & in vivo diagnostic substances • England
Dade Behring Marburg GmbH a company organized under the laws of Germany with its registered offices at Emil von Behring Strabe 76, 35041 Marburg, Germany ("Dade Behring"),
Deal Structure DocumentDeal Structure Document • March 17th, 2003 • Healthcare Technologies LTD • In vitro & in vivo diagnostic substances
In general, Levine Family, LLC, a corporation incorporated under the law of North Carolina ("LF"), which is controlled by Dr. Martin Lee ("Lee"), Savyon Diagnostics Ltd. ("SV") and Healthcare Technologies Ltd., an Israeli publicly traded company (company registration number 52-003621-1) ("HC") agree that LF and HC will establish a new company ("Newco") which will be held in equal parts by HC and LF. LFwill loan to Newco US$ 1.2M (the "LF Loan"). Newco will purchase from SV certain assets of SV in consideration for US$ 1.9M to be paid as follows: US$ 1.2M in cash (using the proceeds of LF Loan), US$ 770K of which will be paid on the Execution Date (as defined below); additional US$ 430K of which, will be paid 90 days thereafter; and an additional US$ 700K in 35 monthly installment of US$ 20K each (with respect to which Newco will issue to SV 35 notes).
ASSET PURCHASE AGREEMENT By and Between OSR Holding Corp. a Delaware corporation (“Buyer”) and OSR Solutions, Inc. a New Jersey corporation (“Seller”) Dated March 2, 2010Asset Purchase Agreement • March 10th, 2010 • Nexgen Biofuels LTD • Industrial organic chemicals • Florida
This Asset Purchase Agreement (“Agreement”) is made as of February 24, 2010, by OSR HOLDING CORP., a Delaware corporation (“Buyer”), OSR SOLUTIONS, INC., a New Jersey corporation (the “Seller”), and the Shareholders of the Company listed in Exhibit 2.6 attached hereto (the “Shareholders”).
DISTRIBUTION AGREEMENTDistribution Agreement • March 17th, 2003 • Healthcare Technologies LTD • In vitro & in vivo diagnostic substances
made and effective as of 1st January, 1999 by and between Amersham Pharmacia Biotech Biotech AB, a Swedish corporation having its address at Bjorkgatan 30, S-751 84 Uppsala, Sweden ("AP Biotech") and Danyel Biotech Ltd, an Israeli corporation having its address at Amargad Building, 32, Shaham Str., Kiryat Matalon, Industrial Zone, Petach Tikva, Israel (the "Distributor").
